DE60002867D1 - Chromeno[4,3,2-de]isochinoline als wirksame dopaminrezeptor-liganden - Google Patents
Chromeno[4,3,2-de]isochinoline als wirksame dopaminrezeptor-ligandenInfo
- Publication number
- DE60002867D1 DE60002867D1 DE60002867T DE60002867T DE60002867D1 DE 60002867 D1 DE60002867 D1 DE 60002867D1 DE 60002867 T DE60002867 T DE 60002867T DE 60002867 T DE60002867 T DE 60002867T DE 60002867 D1 DE60002867 D1 DE 60002867D1
- Authority
- DE
- Germany
- Prior art keywords
- improving
- treating
- compounds
- dopamine receptor
- isochinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000015554 Dopamine receptor Human genes 0.000 title abstract 3
- 108050004812 Dopamine receptor Proteins 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000009084 cardiovascular function Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 210000000750 endocrine system Anatomy 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14016699P | 1999-06-21 | 1999-06-21 | |
| US140166P | 1999-06-21 | ||
| PCT/US2000/016857 WO2000078765A2 (en) | 1999-06-21 | 2000-06-20 | CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60002867D1 true DE60002867D1 (de) | 2003-06-26 |
| DE60002867T2 DE60002867T2 (de) | 2004-02-26 |
Family
ID=22490027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60002867T Expired - Fee Related DE60002867T2 (de) | 1999-06-21 | 2000-06-20 | Chromeno[4,3,2-de]isochinoline als wirksame dopaminrezeptor-liganden |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6413977B1 (de) |
| EP (1) | EP1192161B1 (de) |
| JP (1) | JP2003502428A (de) |
| KR (1) | KR20020010716A (de) |
| AT (1) | ATE240959T1 (de) |
| AU (2) | AU4536599A (de) |
| BR (1) | BR0011711A (de) |
| CA (1) | CA2373497A1 (de) |
| DE (1) | DE60002867T2 (de) |
| DK (1) | DK1192161T3 (de) |
| ES (1) | ES2199837T3 (de) |
| MX (1) | MXPA01013229A (de) |
| NO (1) | NO20016255L (de) |
| NZ (1) | NZ515613A (de) |
| PT (1) | PT1192161E (de) |
| WO (1) | WO2000078765A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082567A2 (en) * | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| AU2004308413A1 (en) * | 2003-12-23 | 2005-07-14 | Darpharma, Inc. | Co-administration of dopamine-receptor binding compounds |
| CA2643300C (en) * | 2006-02-21 | 2011-11-08 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
| WO2010124005A1 (en) | 2009-04-21 | 2010-10-28 | Purdue Research Foundation | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK297275A (da) * | 1974-08-07 | 1976-02-08 | Aspro Nicholas Ltd | Isoquinolinderivater |
| DK272182A (da) * | 1981-06-18 | 1982-12-19 | Univ Northeastern | Fremgangsmaade til fremstilling af oralt effektive aporphin-forbindelser eller dopamin-agonist-forbindelser med ikke aporphinstruktur eller farmaceutisk acceptable syreadditionssalte deraf |
| US5635506A (en) * | 1990-06-26 | 1997-06-03 | Research Corporation Technologies, Inc. | 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
-
1999
- 1999-06-21 AU AU45365/99A patent/AU4536599A/en not_active Abandoned
-
2000
- 2000-06-20 EP EP00942943A patent/EP1192161B1/de not_active Expired - Lifetime
- 2000-06-20 WO PCT/US2000/016857 patent/WO2000078765A2/en active IP Right Grant
- 2000-06-20 KR KR1020017016235A patent/KR20020010716A/ko active IP Right Grant
- 2000-06-20 BR BR0011711-0A patent/BR0011711A/pt not_active IP Right Cessation
- 2000-06-20 ES ES00942943T patent/ES2199837T3/es not_active Expired - Lifetime
- 2000-06-20 DE DE60002867T patent/DE60002867T2/de not_active Expired - Fee Related
- 2000-06-20 DK DK00942943T patent/DK1192161T3/da active
- 2000-06-20 CA CA002373497A patent/CA2373497A1/en not_active Abandoned
- 2000-06-20 JP JP2001504931A patent/JP2003502428A/ja not_active Withdrawn
- 2000-06-20 MX MXPA01013229A patent/MXPA01013229A/es active IP Right Grant
- 2000-06-20 NZ NZ515613A patent/NZ515613A/xx unknown
- 2000-06-20 AU AU57492/00A patent/AU777522C/en not_active Ceased
- 2000-06-20 AT AT00942943T patent/ATE240959T1/de not_active IP Right Cessation
- 2000-06-20 PT PT00942943T patent/PT1192161E/pt unknown
- 2000-06-21 US US09/598,127 patent/US6413977B1/en not_active Expired - Lifetime
-
2001
- 2001-12-20 NO NO20016255A patent/NO20016255L/no not_active Application Discontinuation
-
2002
- 2002-07-02 US US10/188,579 patent/US6916832B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2373497A1 (en) | 2000-12-28 |
| EP1192161B1 (de) | 2003-05-21 |
| US6916832B2 (en) | 2005-07-12 |
| WO2000078765A2 (en) | 2000-12-28 |
| AU777522B2 (en) | 2004-10-21 |
| DE60002867T2 (de) | 2004-02-26 |
| AU777522C (en) | 2005-07-28 |
| NZ515613A (en) | 2004-03-26 |
| MXPA01013229A (es) | 2002-11-04 |
| WO2000078765A3 (en) | 2001-06-28 |
| US20050080266A1 (en) | 2005-04-14 |
| EP1192161A2 (de) | 2002-04-03 |
| NO20016255D0 (no) | 2001-12-20 |
| US6413977B1 (en) | 2002-07-02 |
| JP2003502428A (ja) | 2003-01-21 |
| DK1192161T3 (da) | 2003-08-25 |
| AU5749200A (en) | 2001-01-09 |
| ES2199837T3 (es) | 2004-03-01 |
| ATE240959T1 (de) | 2003-06-15 |
| NO20016255L (no) | 2001-12-20 |
| BR0011711A (pt) | 2002-03-26 |
| PT1192161E (pt) | 2003-09-30 |
| KR20020010716A (ko) | 2002-02-04 |
| AU4536599A (en) | 2001-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE289593T1 (de) | Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden | |
| HK1051684A1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| DE69307340D1 (de) | Chinuclidin derivat als substanz p antagonist | |
| MY107157A (en) | Quinuclidine derivatives. | |
| HUP0004347A2 (hu) | Vegyületek női szexuális diszfunkció kezelésére | |
| AP2002002465A0 (en) | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders. | |
| NO152902C (no) | Analogifremgangsmaae for fremstilling av terapeutisk virksomme 1-alkyl-2-aminotetralinderivater | |
| TNSN99177A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION | |
| DE69706660D1 (de) | N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden | |
| HUP0202534A2 (hu) | Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények | |
| DE60004654D1 (de) | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden | |
| ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
| DE60002867D1 (de) | Chromeno[4,3,2-de]isochinoline als wirksame dopaminrezeptor-liganden | |
| KR950701623A (ko) | 치환된 헥사하이드로벤조페난트리딘 | |
| ATE261443T1 (de) | 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen | |
| ATE221067T1 (de) | Pyrido(2,3-b)(1,4)benzodiazepinone als m2- rezeptorligand zur behandlung neurologischer störungen | |
| IL157363A0 (en) | Novel heterocyclic urea derivatives and their use as dopamine d3 receptor ligands | |
| KR960703912A (ko) | 중추신경계 활성을 갖는 헤테로사이클 아민(heterocyclic amines having central nervous system activity) | |
| WO1996032944B1 (en) | Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor | |
| DE69925160D1 (de) | Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität | |
| KR910020013A (ko) | 피롤로[2,3, -b]인 돌-케톤 및 동족체, 이들의 제조방법 및 약제로서의 이들의 용도 | |
| TNSN00178A1 (en) | Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands | |
| CA2249562A1 (en) | Certain fused pyrrolecarboxamides as gaba brain receptor ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |